|
| |
Epigenomics AGEpigenomics seeks to use its DNA methylation technologies to develop the leading molecular diagnostics products and solution,improving the prognosis of cancer and other common diseasesMolecular diagnostics is a multi-billion euro market opportunity with the greatest future growth expected to be driven by oncology tests. We follow an integrated strategy and business model of partnering our blood-based screening tests and development of our own tissue-based molecular diagnostic products in our SBU Diagnostics. Clinical Solutions offers integrated biomarker solutions, and we aim at establishing a gold standard in DNA methylation via out-licensing.
Own product development & commercialization. The primary focus of product development will be two tissue-based tests directed at prostate and breast cancer molecular classification, leveraging DNA methylation markers and assays that already have significant clinical validation.
Our strategy for own product development builds on creating the organizational infrastructure and developing the required expertise inhouse. Its based on having full control over the entire process of clinical validation and clinical development, as well as regulatory approval, and positioning of the products. At the same time, we expect to work closely with OEM (original equipment manufacturing) partners for key components of our overall product. Both the patient sample processing kits as well as the IVD testing devices will be manufactured for Epigenomics.
| Contact Details: |
| Silke Peitsch VP Human Resources |
| Kleine Präsidentenstr 1 |
| Berlin |
| 10178 |
| Germany |
| Tel: | 49 30 24345-0 |
| Fax: | 49 30 24345-555 |
| Email: | careers@epigenomics.com |
| WWW: | www.epigenomics.de/
|
| |
Recent Publications by Epigenomics AG: |  |
Quantitative DNA methylation profiling on a high-density oligonucleotide microarray.
Recently, the analysis and functional elucidation of CpG island... | 3rd November, 2009
| Science Department, Epigenomics AG, Berlin, Germany.
| Methods Mol Biol. 2010;576:155-70.
DOI Direct Link |
A novel method for sensitive and specific detection of DNA methylation biomarkers based on DNA restriction during PCR cycling.
DNA methylation is an important epigenetic mechanism involved in... | 27th October, 2009
| Epigenomics AG, Berlin, Germany.
| Biotechniques. 2009 Sep;47(3):737-44.
DOI Direct Link |
Analysis of DNA methylation of multiple genes in microdissected cells from formalin-fixed and paraffin-embedded tissues.
A procedure for simultaneous quantification of DNA methylation of several... | 30th May, 2009
| Epigenomics AG, Kleine Prasidentenstr. 1, 10178 Berlin, Germany.
| J Histochem Cytochem. 2009 May;57(5):477-89. Epub 2009 Jan 19.
DOI Direct Link |
DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy.
PURPOSE: We have shown that DNA methylation of the PITX2 gene predicts... | 8th May, 2009
| Epigenomics AG, Berlin, Germany.
| Clin Cancer Res. 2009 Jan 1;15(1):315-23.
DOI Direct Link |
Quantification of methylated DNA by HeavyMethyl duplex PCR.
The HeavyMethyl (HM) assay is a real-time PCR assay suitable for the... | 4th March, 2009
| Epigenomics AG, Berlin, Germany.
| Methods Mol Biol. 2009;507:339-46.
DOI Direct Link |
→View more Epigenomics AG research publications. |
Press Releases on Epigenomics AG:
|
 |
| Reportlinker Adds Molecular Diagnostics: A Dynamic and Rapidly Broadening Market |
29th October, 2009 |
Reportlinker |
-- Major trends in the molecular diagnostics market, such as the increasing
number of tests that are commercially available
Chapter 1
BACKGROUND AND SCOPE
1.1. Background
1.2. Focus
|
| Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C |
8th June, 2009 |
Quest Diagnostics Incorporated |
MADISON, N.J., June 8 /PRNewswire-FirstCall/ -- A study in the June issue of Clinical Gastroenterology and Hepatology, published by Elsevier, demonstrates that the Hepascore(TM) liver fibrosis blood
|
| Quest Diagnostics Introduces First Comprehensive Laboratory Test To Analyze KRAS, NRAS, and BRAF Gene Mutations in Reflex Testing Service |
1st June, 2009 |
Quest Diagnostics Incorporated |
EGFR Pathway Test analyzes in sequential reflex fashion more mutations potentially inhibiting anti-EGFR therapy response in metastatic colorectal cancer patients
MADISON, N.J., June 1 /PRNewswire
|
| Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis |
20th February, 2009 |
Quest Diagnostics |
Study published in New England Journal of Medicine employs Quest Diagnostics' blood-based leukemia testing
MADISON, N.J., Feb. 20 /PRNewswire-FirstCall/ -- Testing of blood specimens may detect
|
| Danish biopharmaceutical company TopoTarget A/S successfully listed on
|
1st July, 2004 |
Topotarget |
Danish biopharmaceutical
company TopoTarget A/S successfully listed on Copenhagen Stock Exchange
July 5th, 2005
Munich: The researched-based
biopharmaceutical company
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 300 times since April 2007, the link to the organisation's website has been followed 39 times Search for more companies in Kleine Präsidentenstr 1 Search for more companies in Berlin This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Epigenomics AG |
